MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
665.89%
Quick Ratio
665.89%
Cash Ratio
649.02%
Debt to Asset Ratio
18.47%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Operating lease right-of-use ass...
    • Prepaid expenses and other curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable and accrued lia...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
33,993,982
8,347,090
13,196,033
12,554,289
Prepaid expenses and other current assets
883,659
920,038
842,432
1,067,409
Total current assets
34,877,641
9,267,128
14,038,465
13,621,698
Property, plant & equipment, net
304,173
339,697
549,405
595,271
Operating lease right-of-use asset
1,433,706
1,483,156
360,671
380,841
Other long-term assets
23,566
29,780
29,780
29,780
Total assets
36,639,086
11,119,761
14,978,321
14,627,590
Accounts payable and accrued liabilities
5,218,681
4,724,826
4,423,548
4,014,682
Warrant liability
17,000
149,000
226,000
801,650
Lease liability, current
2,030
-
100,189
96,034
Total current liabilities
5,237,711
4,873,826
4,749,737
4,912,366
Lease liability, net of current portion
1,529,542
1,528,825
309,397
335,895
Total liabilities
6,767,253
6,402,651
5,059,134
5,248,261
Series d preferred stock, 111.11 shares authorized, issued and outstanding as of march 31, 2026 and december 31, 2025
-
1,382,023
1,382,023
1,382,023
Series e-2 preferred stock, 1,225.00 shares authorized 35.60 and 35.60 shares issued and outstanding as of december 31, 2025 and 2024, respectively-Series E2Preferred Stock
-
-
520,778
-
Series e-2 preferred stock, 1,225.00 shares authorized 35.60 shares issued and outstanding as of march 31, 2026 and december 31, 2025
-
520,778
-
520,778
Common stock, 0.00001 par value 170,000,000 shares authorized 8,252,108 and 4,240,129 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
83
42
42
32
Additional paid-in capital
311,589,849
277,601,713
277,149,844
271,314,776
Accumulated deficit
-281,718,099
-274,787,446
-269,133,500
-263,838,280
Total stockholders' equity
29,871,833
3,335,087
8,537,164
7,997,306
Total liabilities and stockholders' equity
36,639,086
11,119,761
14,978,321
14,627,590
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$33,993,982 (207.89%↑ Y/Y)Prepaid expenses andother current assets$883,659 (-43.95%↓ Y/Y)Total current assets$34,877,641 (176.42%↑ Y/Y)Operating leaseright-of-use asset$1,433,706 (258.20%↑ Y/Y)Property, plant &equipment, net$304,173 (-53.03%↓ Y/Y)Other long-termassets$23,566 (-20.87%↓ Y/Y)Total assets$36,639,086 (167.53%↑ Y/Y)Total liabilities andstockholders' equity$36,639,086 (167.53%↑ Y/Y)Total stockholders'equity$29,871,833 (390.91%↑ Y/Y)Total liabilities$6,767,253 (8.66%↑ Y/Y)Accumulated deficit-$281,718,099 (-8.61%↓ Y/Y)Additional paid-in capital$311,589,849 (17.60%↑ Y/Y)Total currentliabilities$5,237,711 (-10.72%↓ Y/Y)Lease liability, netof current portion$1,529,542 (323.13%↑ Y/Y)Common stock, 0.00001par value...$83 (361.11%↑ Y/Y)Accounts payable andaccrued liabilities$5,218,681 (11.54%↑ Y/Y)Warrant liability$17,000 (-98.45%↓ Y/Y)Lease liability,current$2,030 (-97.79%↓ Y/Y)

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (CLRB)